A Study of a Medicine Called Atirmociclib in Combination With Giredestrant in Adult Participants With ER-positive, HER2-negative Early-stage Breast Cancer
AN INTERVENTIONAL, DOUBLE-BLIND, PLACEBO CONTROLLED, RANDOMIZED, MULTICENTER PHASE 3 STUDY OF ATIRMOCICLIB (PF-07220060) PLUS GIREDESTRANT COMPARED TO GIREDESTRANT MONOTHERAPY AS ADJUVANT TREATMENT IN ADULT PARTICIPANTS WITH ESTROGEN RECEPTOR (ER)-POSITIVE, HER2-NEGATIVE EARLY-STAGE BREAST CANCER WITH MEDIUM OR HIGH RISK OF RECURRENCE (FOURLIGHT-4)
This Phase 3 study will evaluate whether atirmociclib plus giredestrant improves invasive breast cancer-free survival compared with giredestrant alone in adults with ER-positive, HER2-negative early breast cancer at medium or high risk of recurrence.
This is a Phase 3, double blind, placebo controlled study of atirmociclib plus giredestrant vs. giredestrant monotherapy as adjuvant treatment in adult patients with ER+, HER2- early breast cancer. The study plans to enroll 3800 participants randomized 1:1 into one of two treatment arms (Arm A - investigational: atirmociclib plus giredestrant taken continuously in a 28-day cycle) or (Arm B - comparator: placebo plus giredestrant taken continuously in a 28-day cycle). Participants may be treated with atirmociclib/placebo up to 3 years and giredestrant up to 5 years followed by long term follow up for survival and evaluation of recurrence of disease.
연구 개요
상태
정황
연구 유형
등록 (추정된)
단계
- 3단계
연락처 및 위치
연구 연락처
- 이름: Pfizer CT.gov Call Center
- 전화번호: 1-800-718-1021
- 이메일: ClinicalTrials.gov_Inquiries@pfizer.com
참여기준
자격 기준
공부할 수 있는 나이
건강한 자원 봉사자를 받아들입니다
연구 대상 성별
설명
KEY INCLUSION CRITERIA
-
Histologically confirmed unilateral primary adenocarcinoma of the breast
- ER-positive by local assessment
- documented HER2-negative
-
Node positive or node negative as defined by:
-
Pathological node positive (microscopic and/or macroscopic tumor involvement >/=pN1)
-
pN0 and pT >1cm with at least one of the following:
- pT4N0 or
- histologically Grade 3 disease or
- high-risk classification based on genomic assay
-
-
Randomization within 16 months of definitive breast surgery
-
If indicated, completed adjuvant and/or neoadjuvant chemotherapy, adjuvant radiation therapy >/= 21 days prior to randomization
KEY EXCLUSION CRITERIA
-
Distant metastases of breast cancer beyond regional lymph nodes
-
Multicentric or multifocal breast cancer if any tumor foci meet pathologic criteria for ER(-) or HER2(+)
-
Clinically significant cardiovascular disease or cardiac repolarization abnormality for 6 months prior to randomization; resting heart rate <50bpm
-
Has received the following prior systemic anti-cancer therapy for breast cancer
- prior atirmociclib, giredestrant, other investigational anti-cancer agent
- prior treatment with olaparib
NOTES:
- short course of prior neo/adjuvant CDK4/6 inhibitor treatment (</=8 weeks) is permitted; 10-day washout period required
- short course of prior neoadjuvant and/or adjuvant ET (</=18 weeks) is permitted; 35-day washout period for tamoxifen is required
-
Prior treatment with investigational product within 30 days or 5 half-lives
공부 계획
연구는 어떻게 설계됩니까?
디자인 세부사항
- 주 목적: 치료
- 할당: 무작위
- 중재 모델: 병렬 할당
- 마스킹: 네 배로
무기와 개입
참가자 그룹 / 팔 |
개입 / 치료 |
|---|---|
|
실험적: Arm A : Atirmociclib + giredestrant
Atirmociclib tablet given orally twice daily, plus giredestrant capsule given orally once per day |
Atirmociclib tablet given orally twice daily, plus giredestrant capsule given orally once per day
다른 이름들:
giredestrant capsule given once a day |
|
활성 비교기: Arm B: Placebo for atirmociclib + giredestrant
Placebo atirmociclib tablets given orally twice a day plus giredestrant capsule given once a day |
giredestrant capsule given once a day Atirmociclib placebo tablet given twice a day |
연구는 무엇을 측정합니까?
주요 결과 측정
결과 측정 |
측정값 설명 |
기간 |
|---|---|---|
|
Invasive Breast Cancer Free Survival (iBCFS)
기간: From randomization to first iBCFS event, up to 16 years
|
iBCFS is defined as the time from the date of randomization to the date of first documented occurrence of invasive ipsilateral breast tumor recurrence, local-regional invasive breast cancer recurrence, invasive contralateral breast cancer, distant recurrence, or death from any cause, as determined by investigator assessment per STEEP v2.0 criteria |
From randomization to first iBCFS event, up to 16 years
|
2차 결과 측정
결과 측정 |
측정값 설명 |
기간 |
|---|---|---|
|
Invasive Disease Free Survival (iDFS)
기간: From randomization to first iDCFS event, up to 16 years
|
iDFS defined as the time from the date of randomization to the date of first documented occurrence of invasive ipsilateral breast tumor recurrence, local-regional invasive breast cancer recurrence, invasive contralateral breast cancer, distant recurrence, second primary invasive non-breast cancer, or death from any cause, as determined by investigator assessment per STEEP v2.0 criteria |
From randomization to first iDCFS event, up to 16 years
|
|
Disease Recurrence Free Survival (DRFS)
기간: From randomization to first DRFS event, up to 16 years
|
DRFS as per investigator assessment, defined as the time from the date of randomization to the date of distant recurrence as determined by investigator assessment or death from any cause, whichever occurs first |
From randomization to first DRFS event, up to 16 years
|
|
Overall survival (OS)
기간: From randomization to death from any cause, up to 16 years
|
OS is defined as the time from the date of randomization to the date of death due to any cause |
From randomization to death from any cause, up to 16 years
|
|
Number and percentage of Participants with Treatment-Emergent Adverse Events (AEs)
기간: From start of treatment until 28 days after last dose of study treatment, up to 5 years
|
Type, incidence, severity of AE graded by NCI CTCAE v 5.0, seriousness and relationship to study intervention |
From start of treatment until 28 days after last dose of study treatment, up to 5 years
|
|
Percentage of participants With Clinical Laboratory Abnormalities
기간: From start of treatment until 28 days after last dose of study treatment, up to 5 years
|
From start of treatment until 28 days after last dose of study treatment, up to 5 years
|
|
|
Percentage of Participants With ECG abnormalities
기간: From start of treatment until 28 days after last dose of study treatment, up to 5 years
|
From start of treatment until 28 days after last dose of study treatment, up to 5 years
|
|
|
Patient Reported Outcomes (PRO)
기간: From start of treatment until 28 days after last dose of study treatment, up to 5 years
|
Change from baseline in participant reported total score, well-being subscales and symptoms scores and TOI per FACT-ES |
From start of treatment until 28 days after last dose of study treatment, up to 5 years
|
|
Pre-dose Plasma Concentration (Ctrough) of atirmociclib
기간: Cycle 1 Day 15, Cycle 2 Day 1, and Cycle 3 Day 1; Cycle is defined as 28 days
|
Cycle 1 Day 15, Cycle 2 Day 1, and Cycle 3 Day 1; Cycle is defined as 28 days
|
공동 작업자 및 조사자
스폰서
수사관
- 연구 책임자: Pfizer CT.gov Call Center, Pfizer
간행물 및 유용한 링크
연구 기록 날짜
연구 주요 날짜
연구 시작 (추정된)
기본 완료 (추정된)
연구 완료 (추정된)
연구 등록 날짜
최초 제출
QC 기준을 충족하는 최초 제출
처음 게시됨 (실제)
연구 기록 업데이트
마지막 업데이트 게시됨 (실제)
QC 기준을 충족하는 마지막 업데이트 제출
마지막으로 확인됨
추가 정보
이 연구와 관련된 용어
추가 관련 MeSH 약관
기타 연구 ID 번호
- C4391026
개별 참가자 데이터(IPD) 계획
개별 참가자 데이터(IPD)를 공유할 계획입니까?
IPD 계획 설명
Pfizer will provide access to individual de-identified participant data and related study documents (e.g. protocol, Statistical Analysis Plan (SAP), Clinical Study Report (CSR)) upon request from qualified researchers, and subject to certain criteria, conditions, and exceptions. Further details on Pfizer's data sharing criteria and process for requesting access can be found at: https://www.pfizer.com/science/clinical_trials/trial_data_and_results/data_requests.
약물 및 장치 정보, 연구 문서
미국 FDA 규제 의약품 연구
미국 FDA 규제 기기 제품 연구
이 정보는 변경 없이 clinicaltrials.gov 웹사이트에서 직접 가져온 것입니다. 귀하의 연구 세부 정보를 변경, 제거 또는 업데이트하도록 요청하는 경우 register@clinicaltrials.gov. 문의하십시오. 변경 사항이 clinicaltrials.gov에 구현되는 즉시 저희 웹사이트에도 자동으로 업데이트됩니다. .